Angela Vollstedt

Director, Cell & Gene Therapies Portfolio Management at Novartis

Speaker

A microbiologist and biochemist by training from the University of Cambridge, UK, Angela holds a PhD in bacterial secretory protein production from the Research Center Juelich, Germany. After more than 15 years in biopharmaceutical development and strategic business development at Sandoz and Novartis, she joined Novartis Cell & Gene Therapies Portfolio Management to advance the field of autologous CAR-T cell therapy development using innovative expansionless CAR-T manufacturing technology. In this role, she led the novel CAR-T manufacturing roll-out into clinical development and advanced multiple early-stage CAR-T programs leveraging T-Charge platform technology.